2Tzukerman MT, Esty A,Santiso- Mere D et al ,Human estrogen receptor transcriptional capacity is determined by both cellular and promoter context and medicated by two functionally distinct intra molecular regions. MolEndocrinol, 1994,8( 1 ) : 21.
7Love RR, Mazess rb, Barden HS et al . Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Eng J Med, 1992,326:852.
9Sararto T, Blomqvist C, Ehnholm C et al . Antiatherogeme effects of adjuvant antiestrogens; a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with no-de-positive breast cancer. J Clin Oncol, 1996,14:429.
10Butmell Charles A, Hendriksen Barry A, Larsen Samuel D. Framleithsla og kristalform af 2 - methyl - thteno - bensodiasepin. US Patent, IS4446,1997.01.
二级参考文献81
1Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science, 2002,295(5564) : 2465-2468.
2Hudelist G, Czerwenka K, Kubista E, et al. Expression of sex steroid receptor and their co-factors in normal and malignam breast tissue: AIBI is a carcinoma-specific coactivator. Breast Cancer Res Treat, 2003,78(2) : 193-204.
3Azorsa DO, Cuniiffe HE, Meltzer PS. Association of steroid receptor coactivator AIB1 with estrogen receptor-alpha in breast cancer cells. Breast Cancer Res Treat, 2001,70(2) :89-101.
4Deblois G, Giguere V. Ligand-independent coactivation of ERalpha AF-1 by steroid receptor RNA activator (SRA) via MAPK activation. J Steroid Biochem Mol Biol,2003, 85(2-5) : 123-131.
5Santen IKI, Song IGX, McPherson R, et al. The role of mitogenactivated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol, 2002,80(2): 239-256.
6Hayes DF, Thor AD. C-erbB-2 in breast cancer: development of a clinically useful marker. Semin Oncol, 2002,29 (3) : 231-245.
7Love RR, Duc NB, Havighurst TC, et al. Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in esstrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncoh 2003,21(3) :453-457.
8Osborne CK, Bardou V, Hopp TA, et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst, 2003, 9.5 (5): 353-361.
9Schiff R, Maasarweh S, Shou J, et al. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate respond. Clin Cancer Res, 2003, 9 ( Pt2 ) : 447s-454s.
10Iwase H, Zhaatg Z, Ornoto Y, et al. Clinical significance of the expression of estrogen receptors alpha and beta for endocrine therapy of breast cancer. Cancer Chemother Pharmacol, 2003, 52 ( Suppll ) :S34-38.
